Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis
about
Pitavastatin in cardiometabolic disease: therapeutic profileDietary fructose and glucose differentially affect lipid and glucose homeostasisEffects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefitStabilization of high-risk plaquesStatins in cardiometabolic disease: what makes pitavastatin different?Cholesterol: the good, the bad, and the ugly - therapeutic targets for the treatment of dyslipidemiaRegression of atherosclerosis: insights from animal and clinical studiesThe prevention and regression of atherosclerotic plaques: emerging treatments.Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protectionThe therapeutic role of niacin in dyslipidemia managementComparison of the Risk of Gastrointestinal Bleeding among Different Statin Exposures with Concomitant Administration of Warfarin: Electronic Health Record-Based Retrospective Cohort StudyStatins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophagesMeta-analysis of genome-wide association studies of HDL cholesterol response to statins.Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study.The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline.Clinical Outcomes in Patients with Intermediate Coronary Stenoses: MINIATURE Investigators (Korea MultIceNter TrIal on Long-Term Clinical Outcome According to the Plaque Burden and Treatment Strategy in Lesions with MinimUm Lumen ARea lEss Than 4 mmEffect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.Longitudinal paths to the metabolic syndrome: can the incidence of the metabolic syndrome be predicted? The Baltimore Longitudinal Study of Aging.Triglycerides and HDL cholesterol: stars or second leads in diabetes?A pro-atherogenic HDL profile in coronary heart disease patients: an iTRAQ labelling-based proteomic approachEffects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-AtheroRapid regression of atherosclerosis with MTP inhibitor treatment.Is High Serum LDL/HDL Cholesterol Ratio an Emerging Risk Factor for Sudden Cardiac Death? Findings from the KIHD Study.HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells.Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.Gene activation regresses atherosclerosis, promotes health, and enhances longevity.Differential effect of Pistacia vera extracts on experimental atherosclerosis in the rabbit animal model: an experimental studyRegulation of high-density lipoprotein on hematopoietic stem/progenitor cells in atherosclerosis requires scavenger receptor type BI expression.Adding monounsaturated fatty acids to a dietary portfolio of cholesterol-lowering foods in hypercholesterolemiaTriglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for managementCombination therapy of statins and fibrates in the management of cardiovascular risk.Effect of high-intensity statin treatment in rheumatoid arthritis: a case with possible coronary atheroma regression and progression of rheumatoid valve degenerationEffect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database.Chinese herbal medicine for impaired glucose tolerance: a randomized placebo controlled trialMorphological changes of parotid gland in experimental hyperlipidemia.Integrative Treatments to Reduce Risk for Cardiovascular DiseaseAre Additional Lipid Measures Useful?Low HDL-C level is associated with the development of intracranial artery stenosis: analysis from the Chinese IntraCranial AtheroSclerosis (CICAS) studyRosuvastatin and progression of atherosclerosis.
P2860
Q21246037-3A17E1B9-13A1-4F46-B365-C59778E71A6CQ24642206-1B65058A-50C1-493E-BE8D-2B3673CB23EFQ24650533-CB3AF813-98BE-4894-AD99-49577429EACAQ26738584-09C3D3C6-E038-4AC1-8740-941493F10136Q27010638-5F181C7D-5218-4A63-8D6C-9A27B4AF21FCQ27013494-49A014D7-329C-4015-9000-4C690E4E5B60Q27028112-E88B2B96-C939-40BF-9061-F91084AF3B46Q27691367-F6FA5D74-191B-46B4-8B79-22A60E144DB5Q28235893-00302B10-EDA1-459B-9985-60ECB16C31E7Q28304559-5CF07476-6EC2-4B88-8289-EB4AD1889260Q28552407-A89A230E-F7B0-4816-A873-AB07D4AE4068Q28741815-A61E8940-B1FA-4E36-ACF7-A57BCB1FF3B1Q30276013-A024391C-3D4D-441E-AF25-D7FC06FF758FQ30364133-90757D69-9604-4DED-BCEA-68A3890CF2E3Q30425097-5CAB4061-C9FD-4E82-BC40-820DBB56F92EQ30437813-952E46AE-37CD-4258-A54A-BFFBFEB73BCDQ33537687-87282B88-2524-4D10-9DFE-FDBDB0D17848Q33590777-599062BE-A925-435B-82B5-428DADC13A3DQ33597936-1D0BC00C-413C-449D-A2CE-68A8C13302F7Q33610637-EBB93141-5489-47F3-88FE-6AD2DFF3CCFDQ33655192-88A865B8-895E-43E6-A925-303750852607Q33693952-B90C8DE0-89E4-4AD0-8660-E1EE6EF4C570Q33719335-848F4A2C-1680-43A0-9F12-91D2D956B59CQ33752274-44A79842-0763-409B-A2A3-AD71F13F0552Q33868782-D6ACFB29-3E27-45A9-BAAD-74094BEE3772Q33972551-0B3D6FB8-A50B-4F94-AAE4-1707DDB5C0F1Q34020016-27D9FDD9-154D-4A41-82DF-2B2B5439E229Q34049699-ADC2586D-64D3-4212-828D-B3DD7B23B8DEQ34076242-CF7AC651-2B0B-4902-AE3E-C14109D8EB7FQ34147410-20B9A52C-2AAF-42CB-9321-2A84EA1B56BCQ34181381-031AE3FC-6FFE-4AD2-925E-DC59C9A427DAQ34305993-95061DCF-F2F2-4231-A274-DE19447DFF0FQ34530587-83FE5B2D-0544-41FA-A3D9-FBB2BA3A18A9Q34559971-7826E95A-5C3F-406C-911C-8ED4F05A9425Q34721973-8E2953C8-1C67-4D36-97A9-73D6B8EA8F3FQ34725583-24C7A08D-2FF0-4826-ABA8-76C2E692F58FQ34730309-2BD2104A-53A7-4204-9FB2-AC3B36E71F3DQ34730419-7B9EB2E7-00A5-4338-9D72-EB98DF797620Q34731504-3FDCA173-5C15-421B-84BE-5D7509B3E9A1Q34802802-BCF84787-1620-4987-B8B8-23E9E2E0130E
P2860
Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis
description
article publié dans la revue scientifique Journal of the American Medical Association
@fr
im Februar 2007 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published in The Journal of the American Medical Association
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 2007
@uk
name
Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis
@en
Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis
@nl
type
label
Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis
@en
Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis
@nl
prefLabel
Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis
@en
Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis
@nl
P2093
P50
P356
P1476
Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis
@en
P2093
Adam W Grasso
E Murat Tuzcu
Kathy Wolski
Milind Y Desai
Samir R Kapadia
Stanley L Hazen
Steven E Nissen
Tingfei Hu
P304
P356
10.1001/JAMA.297.5.499
P407
P577
2007-02-01T00:00:00Z